Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...

Ginkgo Bioworks Holdings, Inc.’s DNA share price has surged by 13.55%, which has investors questioning if this is right time to sell.

北京时间2025年1月17日，Ginkgo Bioworks Holdings, Inc.（股票代码：DNA.us）在美股市场上经历了显著的股价波动，盘中急速上升5%，当前报9.77美元/股，成交量达33.0462万股，换手率为0.57%，振幅则达7.66%。这一市场表现引发了投资者的广泛关注，尤其是在当前生物技术行业整体小幅下跌0.16%的背景下，这一异动格外引人注目。

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

北京时间2025年02月01日04时02分，Ginkgo Bioworks Holdings, Inc.（DNA.us）股票出现波动，股价大幅下跌5.00%。截至发稿，该股报13.22美元/股，成交量117.432万股， 换手率 2.04%，振幅9.78%。

北京时间2025年01月17日01时55分，Ginkgo Bioworks Holdings, Inc.（DNA.us）股票出现波动，股价快速上涨5.00%。截至发稿，该股报9.77美元 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...